Skip to main content
SpringerLink
Log in

Overview of Radioimmunotherapy in Advanced Breast Cancer Using I-131 Chimeric L6

  • Chapter
Book cover Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 353))

Abstract

131I chimeric L6 (ChL6) monoclonal antibody (MoAb) therapy has been performed in 12 patients with advanced, metastatic breast cancer. The protocol was designed to determine the maximum tolerated dose (MTD) of radioimmunotherapy that could be administered at 4 intervals. Ten patients received 20 - 70 mCi/m2 of 131I ChL6. Two of the patients received granulocyte colony stimulating factor (GCSF) on days 10-20 post therapy. The MTD for two doses was 60 mCi/m2 and thrombocytopenia was the dose limiting toxicity in the absence of marrow reconstitution with stem cells. Two patients received 150 mCi/m2 with autologous peripheral blood stem cell support 7 and 9 days post treatment. The MTD has not been reached for 131I-ChL6 with autologous stem cell support. In the 12 patients treated with 131I ChL6, six patients (50%) had measurable tumor regressions greater than 30% of the sum of the largest two dimensional products for measurable tumors. Four of these 6 patients had a partial response (PR), i.e., ≤ 50% reduction in tumor size.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. I.C. Henderson, J.R. Harris, D.W. Kinne, and S. Hellman. Cancer of the breast, in: V.T. Devita, S. Hellman, S.A. Rosenberg, eds., Cancer Principles and Practice of Oncology. JB Lippincott, Philadelphia 1197–1261 (1989).

    Google Scholar 

  2. E. Silverberg, C.C. Boring, and T.S. Squires. Cancer statistics. CA 40:9–26 (1990).

    CAS  Google Scholar 

  3. K.H. Antman. Dose intensive therapy in breast cancer, in: “High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cell,” J.O. Armitage, K.H. Antman, eds., Williams & Wilkins, Baltimore 701–718 (1992).

    Google Scholar 

  4. M.S. Fox. On the diagnosis and treatment of breast cancer. JAMA 241:489–494 (1979).

    Article  PubMed  CAS  Google Scholar 

  5. J J. Tjandra and I.F.C. McKenzie. Murine monoclonal antibodies in breast cancer: an overview. Br J Surg 75:1067–1077 (1988).

    Article  PubMed  CAS  Google Scholar 

  6. A. Thor, M.O. Weeks, and J. Schlom. Monoclonal antibodies and breast cancer. Seminars in Oncology 13:393–401 (1986).

    PubMed  CAS  Google Scholar 

  7. L.M. Weiner, J. O’Dwyer, J. Kitson, R.L. Comis, A.E. Frankel, R.J. Bauer, M.S. Konrad, and E.S. Groves. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res 49: 4062–4067 (1989).

    PubMed  CAS  Google Scholar 

  8. J. Malamitsi, D. Skarlos, S. Fotiou, P. Papakostas, G. Aravantinos, D. Vassilarou, J. Taylor-Papadimitriou, K. Koutoulidis, G. Hooker, and D. Snook. Intracavitary use of two radiolabeled tumor-associated monoclonal antibodies. J Nucl Med 29:1910–1915 (1988).

    Google Scholar 

  9. B.J. Gould, M.J. Borowitz, E.S. Groves, P.W. Carter, D. Anthony, L.M. Weiner, and A.E. Frankel. Phase I study of antibreast immunotoxin by continuous infusion. J of the NCI 81:775–781 (1989).

    CAS  Google Scholar 

  10. B.P. Avner, S.K. Liao, B. Avner, K. DeCall, and R.K. Oldham. Therapeutic murine monoclonal antibodies developed for individual cancer patients. J of Biological Resp Mod 8:25–36 (1989).

    CAS  Google Scholar 

  11. S.J. DeNardo, L.F. O’Grady, D.J. Macey, L.A. Kroger, G.L. DeNardo, K.R. Lamborn, N.B. Levy, S.L. Mills, I. Hellstrom, and K.E. Hellstrom. Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy. Nucl Med Biol 18:621–631 (1991).

    CAS  Google Scholar 

  12. S.J. DeNardo, G.R. Mirick, L.A. Kroger, L.F. O’Grady, K.L. Erickson, A. Yuan, K.R, Lamborn, I Hellstrom, K.E. Hellstrom and G.L. DeNardo. The biologic window for ChL6 radioimmunotherapy. Cancer (1994).

    Google Scholar 

  13. I. Hellstrom, D. Horn, P. Linsley, J. P. Brown, V. Brankovan, and K.E. Hellstrom. Monoclonal antibodies raised against human lung carcinomas. Cancer Res 46:3917–3923 (1986).

    PubMed  CAS  Google Scholar 

  14. I. Hellstrom, P.L. Beaumier, and K.E. Hellstrom. Antitumor effects of L-6, an IgG2a antibody that reacts with most human carcinomas. Proc Natl Acad Science USA 83: 7059–7063 (1986).

    Article  CAS  Google Scholar 

  15. G.P. Adams, S.J. DeNardo, A. Amin, L.A. Kroger, G.L. DeNardo, I. Hellstrom, and K.E. Hellstrom. Comparison of the pharmacokinetics in mice and the biological activity of murine L-6 and human-mouse chimeric Ch L6 antibody. Antibod Immunoconjug Radiopharm 5:81–95 (1992).

    CAS  Google Scholar 

  16. A.Y. Liu, R.R. Robinson, K.E. Hellstrom, E.D. Murray, Jr., C.P. Chang, and I. Hellstrom. Chimeric mouse-human IgGl antibody that can mediate lysis of cancer cells. Proc Natl Acad Science USA 84:3439–3443 (1987).

    Article  CAS  Google Scholar 

  17. W.M. Hunter and F.C. Greenwood. Preparation of iodine-131 labelled growth hormone of high specific activity. Nature 194:495 (1962).

    Article  PubMed  CAS  Google Scholar 

  18. S.L. Mills, S.J. DeNardo, G.L. DeNardo, A.L. Epstein, J-S. Peng, and D. Colcher. I-123 radiolabelling of monoclonal antibodies for in vivo procedures. Hybridoma 5:265–275 (1986).

    Article  PubMed  CAS  Google Scholar 

  19. P.L. Beaumier, D. Neuzil, H-M. Yang, E.A. Noll, R. Kishore, J.F. Eary, K.A. Krohn, W.B. Nelp, K.E. Hellstrom, and I. Hellstrom. Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies. J Nucl Med 27: 824–828 (1986).

    PubMed  CAS  Google Scholar 

  20. D J. Macey, G.L. DeNardo, and S J. DeNardo. A treatment planning program for radioimmunotherapy. Front Radiat Ther Oncol 24:123–131 (1990).

    PubMed  CAS  Google Scholar 

  21. A. Louderback, E.H. Mealy, and P.H. Wiernik. A new dye-binding technique using bromocresyl purple for determination of albumin in serum. Clin Chem 14:793–794 (1968).

    Google Scholar 

  22. P. Yam L.D. Petz, and N.R. Cooper. The relationship between hemolytic and immunodiffusion methods for measurement of C4 in patients with immunologic disorders. Am J Clin Path 64:351–357 (1975).

    PubMed  Google Scholar 

  23. A. Linde, B. Anderson, S.B. Svenson, H. Ahrne, M. Carlsson, P. Forsberg, et al. Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. J Infec Dis 165:994–1000 (1992).

    Article  CAS  Google Scholar 

  24. A. Kessinger, J.O. Armitage, J.D. Landmark, D.M. Smith, and D.D. Weisenberger. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 71:723–727 (1988).

    PubMed  CAS  Google Scholar 

  25. A. Elias, L. Ayash, K. Anderson, C. Wheeler, G. Schwartz, I. Teppler, C. Lynch, M. Hunt, S. Pap, J. Deary, J Pelaez, L. Schnipps, J Griffin, E. Frei, and K. Antman. Hematologic support during high dose intensification for breast cancer: Recruitment od peripheral blood progenitor cells by GM-CSF and chemotherapy. Blood 76 (suppl):536a (1990).

    Google Scholar 

  26. S.J. DeNardo, K.A. Warhoe, L.F. O’Grady, G.L. DeNardo, I. Hellstrom, K.E. Hellstrom, and S.L. Mills. Radioimmunotherapy with 1-131 chimeric L-6 in advanced breast cancer, in: “Breast Epithelial Antigens,” R.L. Ceriani, eds., Plenum Press, New York, pp. 227–232 (1991).

    Chapter  Google Scholar 

  27. G.E. Goodman, I. Hellstrom, C. Nicaise, L. Brodzinsky, D. Hummel, and K.E. Hellstrom. Phase I trial of murine monoclonal antibody L-6 in breast, colon, ovarian,and lung cancer. J Clin Oncol 50:2449–2454 (1990).

    Google Scholar 

  28. G.E. Goodman, I. Hellstrom, D.E. Yelton, J.L. Murray, S. O’Hara, E. Meaker, L. Zeigler, P. Palazollo, C. Nicaise, J. Usakewicz, et al. Phase I trial of chimeric (human-mouse) monoclonal antibody L-6 in patients with non-small-cell lung, colon, and breast cancer. Cancer Immunol Immunother 36(4):267–273 (1993).

    Article  PubMed  CAS  Google Scholar 

  29. G.L. DeNardo, S.J. DeNardo, N. Levy. Treatment of B cell malignancies with 131I-Lym-l and mechanisms for improvement. in: “Monoclonal Antibodies 2, Applications in Clinical Oncology,” A. Epenetos, ed., Chapman & Hall Medical, New York, pp. 355–367 (1993).

    Google Scholar 

  30. J.A. Ledermann, R.H.J Begent, K.D. Bagshawe, S.J. Riggs, F. Searle, M.G. Glaser, AJ. Green and R.G. Dale. Repeated antitumor antibody therapy in man with suppression of the host response by cyclosporin A. Brit J Cancer 58: 654–657 (1988).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of California Davis Medical Center, Sacramento, California, USA

    S J. DeNardo, L. F. O’Grady, C. M. Richman & G. L. DeNardo

Authors
  1. S J. DeNardo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. F. O’Grady
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. M. Richman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. L. DeNardo
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cancer Research Fund of Contra Costa, Walnut Creek, California, USA

    Roberto L. Ceriani

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer Science+Business Media New York

About this chapter

Cite this chapter

DeNardo, S.J., O’Grady, L.F., Richman, C.M., DeNardo, G.L. (1994). Overview of Radioimmunotherapy in Advanced Breast Cancer Using I-131 Chimeric L6. In: Ceriani, R.L. (eds) Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment. Advances in Experimental Medicine and Biology, vol 353. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2443-4_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2443-4_19

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6038-4

  • Online ISBN: 978-1-4615-2443-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation